March 28, 2022 8:07am
A list that keeps growing: Resistance mired by sentiment, focus, earnings and low volume volatility, geopolitics, accentuated by quarterly option expirations on Friday and potentially subverted by the March jobs and economic reporting
Pre-open indications: 5 SELLs, 1 BUY and 1 pimp/pump/promote
Earnings: Brainstorm Cell Therapeutics (BCLI) and Verastem Oncology (VSTM)
RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.
Just the facts … I ask questions and note the indications of what could happen …
Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.
Dow futures are UP +0.18% (+61 points), S&P futures are UP +0.21% (+9 points) and NASDAQ futures are UP +0.25% (+38 points)
Stock futures are barely moving although up on Monday morning with a week filled with key economic reports kicking-off, and possibilities of the Fed’s planned interest rate hikes,
European stocks moved higher as investors continue watching the war between Ukraine and Russia,
Asia-Pacific stocks were trading mixed as profits at China’s industrial firms rose 5.0% for the January to February period as compared with a year earlier, according to data released Sunday while Japan slipped, Australia while Covid shut-down Shanghai closed barely higher
Henry’omics:
Last Friday, the Dow gained +153.30 points, or 0.44%, the S&P 500 advanced +22.90 points or +0.5% while the Nasdaq dived -22.54 points or -0.16% but still finished the week in the green.
The stock market rally has showed resilience in the face of rising crude oil prices and surging Treasury yields. That is, so far. But don't be complacent. A relentless rise in Treasury yields is hard for the stock market to shrug off indefinitely, especially growth names. <IBD>
RegMed Investors’ (RMi) closing bell: “the cell and gene therapy sector got robbed again of share pricing value. As I stated this a.m., “The alternating positive and negative closes defines the infection of sentiment as it doesn’t take much to bounce or depress the cell and gene therapy sector.” … https://www.regmedinvestors.com/articles/12361
Ebb and flow –
· March – 10 negative and 9 positive closes
· February stats: 11 negative, 8 positive closes and 1 holiday
· January stats: 2 holidays, 1 neutral, 13 negative and 6 positive closes
Research Notes:
RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628 ... 31 total to date
Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS
BUY:
- AxoGen (AXGN -$0.10) has a positive +$0.18 or +2.32% pre-market indication,
SELL:
- Ionis Pharmaceuticals (IONS-$0.25) has a negative -$2.08 or -5.67% pre-market indication,
- Intellia Therapeutics (NTLA -$1.36) with a negative -$1.97 or -2.79% pre-open indication
- BioLife Solutions (BLFS -$1.16) has a negative -$0.39 or -1.87% pre-market indication,
- Mesoblast (MESO -$0.13) has a negative -$0.19 or -4.29% pre-market indication,
- uniQure NV (QURE +$0.59) with a negative -$0.55 or -3.28% pre-market indication
Pimp/Pump and Promote:
- Biostage (OTCQB: BSTG) closed up +$0.44 with 1,978 shares traded after Thursday’s flat with 34 shares traded after Wednesday with 4 shares traded, Tuesday’s down -$0.17 with 202 shares traded and Monday’s flat with 5 shares traded. WHY BUY these shares of a company with a 3-year-old IND, NO clinical trial initiation, a terminal death lawsuit overhang and a dwindling cash position?
The BOTTOM LINE: Last week: what with the alternating loses?
· Friday closed negative with 7 incliners and 28 decliners
· Thursday closed positive with 28 incliners, 6 decliners and 1 flat
· Wednesday closed negative with 6 incliners, 28 decliners and 1 flat
· Tuesday closed positive with 31 incliners and 4 decliners
· Monday closed negative with 2 incliners, 31 decliners and 2 flats
Resistance, sentiment algorithms and electronic trading numbing the share pricing as BOREDOM inhabits the sector.
It's impressive that the Nasdaq in particular has been able to rally so strongly in the past couple of weeks despite Treasury yields soaring over that time. It's hard to believe that growth stocks could continue to advance if bond yields continuing rising at such a brisk pace. But that could have been said a week ago. <IBD>
Hold-on (to the railing) as a portfolio weather these volatile sessions is an ordinary practice.
Again, I reiterate, “I’m never totally wrong but, not always wholly right after Monday, Tuesday, Wednesday, Thursday’s closes and last Friday’s week end.
There are still plenty of hurdles i.e., as economy faces struggles, European war headlines - hopes of progress in talks between the two sides last week fading, and maybe further earnings surprises - another four (4) are due.
There is no clear trend ….
RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider their investment objectives.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.
